Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis

Journal of Hepatology

Volumn 58, Issue 5, 2013, Pages 956-961

  Waidmann, Oliver ^a   Brunner, Friederike ^a   Herrmann, Eva ^a   Zeuzem, Stefan ^a   Piiper, Albrecht ^a   Kronenberger, Bernd ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Liver cirrhosis; Macrophage activation; Portal hypertension; sCD163; Variceal bleeding

Indexed keywords

C REACTIVE PROTEIN; CD163 ANTIGEN; SOLUBLE CD163 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASCITES; BACTERIAL PERITONITIS; BLOOD SAMPLING; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS VARICES BLEEDING; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; LIVER CIRRHOSIS; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOLOGICAL MARKERS; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MACROPHAGE ACTIVATION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84876291209     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.01.005     Document Type: Article

References (22)

1. A. Cárdenas, and P. Ginès Management of patients with cirrhosis awaiting liver transplantation Gut 60 2011 412 421
2. European Association for the Study of the Liver EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis J Hepatol 53 2010 397 417
3. P.S. Kamath, R.H. Wiesner, M. Malinchoc, W. Kremers, T.M. Therneau, and C.L. Kosberg A model to predict survival in patients with end-stage liver disease Hepatology 33 2001 464 470
4. P.S. Kamath, and W.R. Kim The model for end-stage liver disease (MELD) Hepatology 45 2007 797 805
5. M.R. Al Sibae, and M.S. Cappell Accuracy of MELD scores in predicting mortality in decompensated cirrhosis from variceal bleeding, hepatorenal syndrome, alcoholic hepatitis, or acute liver failure as well as mortality after non-transplant surgery or TIPS Dig Dis Sci 56 2011 977 987
6. G. Garcia-Tsao, and J. Bosch Management of varices and variceal hemorrhage in cirrhosis N Engl J Med 362 2010 823 832
7. A. Perello, A. Escorsell, C. Bru, R. Gilabert, E. Mointinho, and J.C. Garcia-Pagan Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis Hepatology 30 1999 1393 1397
8. C. Zhang, D. Thabut, P.S. Kamath, and V.H. Shah Oesophageal varices in cirrhotic patients: from variceal screening to primary prophylaxis of the first oesophageal variceal bleeding Liver Int 31 2011 108 119
9. K. Wallace, A.D. Burt, and M.C. Wright Liver fibrosis Biochem J 411 2008 1 18
10. A. Klein, M. Zhadkewich, J. Margolick, J. Winkelstein, and G. Bulkley Quantitative discrimination of hepatic reticuloendothelial clearance and phagocytic killing J Leukoc Biol 55 1994 248 252
11. S.K. Moestrup, and H.J. Møller CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response Ann Med 36 2004 347 354
12. L.K. Weaver, K.A. Hintz-Goldstein, P.A. Pioli, K. Wardwell, N. Qureshi, and S.N. Vogel Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163 J Leukoc Biol 80 2006 26 35
13. H.J. Møller Soluble CD163 Scand J Clin Lab Invest 72 2012 1 13
14. H.J. Møller, H. Gronbaek, F.V. Schiødt, P. Holland-Fischer, M. Schilsky, and S. Munoz Soluble CD163 from activated macrophages predicts mortality in acute liver failure J Hepatol 47 2007 671 676
15. P. Holland-Fischer, H. Grønbæk, T.D. Sandahl, S.K. Moestrup, O. Riggio, and L. Ridola Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS Gut 60 2011 1389 1393
16. H. Grønbaek, T.D. Sandahl, C. Mortensen, H. Vilstrup, H.J. Møller, and S. Møller Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis Aliment Pharmacol Ther 36 2012 173 180
17. R.N.H. Pugh, I.M. Murray-Lyon, J.L. Dawson, M.C. Pietroni, and R. Williams Transection of the esophagus in bleeding oesophageal varices Br J Surg 60 1973 648 652
18. R. de Franchis, and Baveno V Faculty Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension J Hepatol 53 2010 762 768
19. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK) J Natl Cancer Inst 97 2005 1180 1184
20. J.P. Cervoni, T. Thévenot, D. Weil, E. Muel, O. Barbot, and F. Sheppard C-reactive protein predicts short-term mortality in patients with cirrhosis J Hepatol 56 2012 1299 1304
21. P. Ginès, A. Cárdenas, V. Arroyo, and J. Rodés Management of cirrhosis and ascites N Engl J Med 350 2004 1646 1654
22. C.J. Steib, A.L. Gerbes, M. Bystron, M. Op den Winkel, J. Härtl, and F. Roggel Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A(2) J Hepatol 47 2007 228 238